Comparative Pharmacology
Head-to-head clinical analysis: CORTAN versus SERNIVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTAN versus SERNIVO.
CORTAN vs SERNIVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
SERNIVO (clobetasol propionate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
5-60 mg orally once daily, titrated to the lowest effective dose. Maintenance: 5-20 mg daily.
Apply a thin layer to affected area twice daily for up to 2 weeks.
None Documented
None Documented
Terminal elimination half-life 1.5–2 hours; clinical context: short duration requires multiple daily doses for sustained effect
Approximately 3 hours (parent drug); clinical duration extended via formulation.
Renal: 80% as metabolites and unchanged drug; biliary/fecal: 20%
Primarily renal excretion of inactive metabolites; <5% unchanged. Minor biliary/fecal elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid